Return to homepagePandemic Pact

Adaptive responses to SARS-CoV-2 variants in the context of hybrid immunity and immune impairment

Grant number: 226137/Z/22/Z

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2023
    2025
  • Known Financial Commitments (USD)

    $3,852,733.63
  • Funder

    Wellcome Trust
  • Principal Investigator

    Prof Alexander Sigal
  • Research Location

    South Africa
  • Lead Research Institution

    Africa Health Research Institute
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SARS-CoV-2 evolved variants that could escape previous immunity and transmit better. This process so far culminated in the Omicron variant, which led to a global infection wave of unprecedented scale. To ensure an effective response to variants, their biology, evolution, and mechanisms of escape must be better understood. It is critical to rapidly determine cross-protection afforded by vaccination or previous infections against emerging variants and understand the mechanisms for that protection or lack thereof. This will require understanding B and T cell targets, as well as how these relate to emerging variation, to quickly model/predict new viral escape mutations. Such a high- resolution response is only possible by combining immunology, virology, T and B cell biology, antibody mapping, and structural biology, and will need to be done for increasingly hybrid-induced immunity. The effort must also benefit young investigators. Specific Aims 1. Perform immunological surveillance of current and emerging variants and predict future mutations which impact antibody and T cell immunity 2. Determine how increasingly complex hybrid immunity functions against current and emerging variants 3. Determine how immune impairment mediated by co-infection with HIV modulates response to variants 4. Promote the next generation of African scientists through cutting- edge research and scientific exchange

28 Publications linked via Europe PMC

Evolution and viral properties of the SARS-CoV-2 BA.3.2 subvariant.

HLA typing of HLA-A, -B, -C, -DPB1, -DQB1 and -DRB1 loci of 226 individuals from three metropolitan areas in South Africa.

Multifaceted B cell response to transient HIV viremia in elite controllers.

Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease.

Evolution and Viral Properties of the SARS-CoV-2 BA.3.2 Subvariant

Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.

SARS-CoV-2 correlates of protection from infection against variants of concern.

SARS-CoV-2 correlates of protection from infection against variants of concern